Table 3 Treatment-related toxicity and treatment compliance
From: Clinical significance of the cachexia index in patients with small cell lung cancer
Adverse event | LD | ED | ||||
|---|---|---|---|---|---|---|
High-CXI group (n = 83) | Low-CXI group (n = 24) | p | High-CXI group (n = 123) | Low-CXI group (n = 37) | p | |
Hematological toxicity ≥ grade 3 | ||||||
 Anemia | 17 (20.5%) | 7 (29.2%) | 0.369 | 21 (17.1%) | 9 (24.3%) | 0.322 |
 Neutropenia | 78 (94.0%) | 21 (87.5%) | 0.375 | 108 (87.8%) | 29 (78.4%) | 0.152 |
 Febrile neutropenia | 16 (19.3%) | 5 (20.8%) | >  0.998 | 17 (13.8%) | 8 (21.6%) | 0.252 |
 Thrombocytopenia | 21 (25.3%) | 7 (29.2%) | 0.704 | 27 (22.0%) | 10 (27.0%) | 0.521 |
Median treatment cycles (IQR) | 6 (4–6) | 5.5 (3–6) | 0.118 | 6 (4–6) | 3 (2–6) | <  0.001 |
Early discontinuation of treatment | 14 (16.9%) | 9 (37.5%) | 0.030 | 14 (11.4%) | 10 (27.0%) | 0.019 |
Treatment-related mortality | 4 (4.8%) | 3 (12.5%) | 0.186 | 3 (2.4%) | 4 (10.8%) | 0.051 |